8-K: Prothena's Parkinson's Drug Prasinezumab Advances to Phase III with Roche Partnership

Prothena Corporation plc announced that its partner Roche will advance prasinezumab, an investigational anti-alpha-synuclein antibody, into Phase III development for early-stage Parkinson's disease.

Summary

• Prothena's partner Roche has decided to advance prasinezumab into Phase III development for early-stage Parkinson's disease.
• This decision is based on data from the Phase IIb PADOVA study and ongoing open-label (OLE) extensions from both PADOVA and the Phase II PASADENA study.
• Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, designed to bind aggregated alpha-synuclein and reduce neuronal toxicity, potentially slowing disease progression.
• The Phase IIb PADOVA study, involving 586 early-stage Parkinson's patients, showed potential clinical efficacy in the primary endpoint of time to confirmed motor progression (HR=0.84 [0.69-1.01]), though it missed statistical significance (p=0.0657).
• In a pre-specified analysis, the effect was more pronounced in the levodopa-treated population (75% of participants), with a HR=0.79 [0.63-0.99], p=0.0431 (nominal).
• Positive trends towards reduced motor progression (30-40% relative reduction versus placebo) were observed at 104 weeks (two years) across overall and levodopa-treated populations, sustained over longer OLE treatment periods.
• The PADOVA study also provided the first biomarker evidence of prasinezumab impacting underlying disease biology.
• Prasinezumab continues to be well tolerated with no new safety signals observed across a safety database of over 900 Parkinson's disease study participants, with more than 750 in open-label treatment and over 500 treated for 1.5-5 years.
• Under the 2013 collaboration agreement, Roche has sole responsibility for developing and commercializing prasinezumab, and Prothena is eligible for double-digit teen royalties on net sales.
• Prothena has earned $135 million to date and is eligible for up to $620 million in additional regulatory and sales milestone payments.
• Parkinson's disease affects over 10 million people globally, is increasing in prevalence, and currently lacks therapies that slow or stop clinical progression.

Sentiment

Score: 9

Explanation: The sentiment is highly positive due to the significant advancement of prasinezumab into Phase III, a critical and high-value stage for a potential first-in-class drug in a large and underserved market. Despite the primary endpoint missing statistical significance in the overall Phase IIb population, the decision to proceed, coupled with positive trends, biomarker evidence, and a statistically significant effect in a key subpopulation, indicates strong confidence from the partner Roche and represents a major positive catalyst for Prothena.

Positives

• Roche's decision to advance prasinezumab into Phase III development signifies strong confidence in the drug's potential.
• Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson's disease progression.
• Data from Phase IIb PADOVA and OLE studies suggest clinical benefit on top of symptomatic treatment in early-stage Parkinson's disease.
• Positive trends towards reduced motor progression were observed at 104 weeks (two years), with effects appearing sustained over longer treatment periods.
• The effect of prasinezumab was more pronounced and statistically significant in the pre-specified analysis of the levodopa-treated population (HR=0.79 [0.63-0.99], p=0.0431).
• PADOVA study provided the first biomarker evidence of prasinezumab impacting underlying disease biology.
• Prasinezumab has a good safety profile, being well tolerated with no new safety signals observed across a large patient database.
• Prothena is eligible for significant future milestone payments (up to $620 million) and double-digit teen royalties on net sales.
• Prothena retains an option to co-promote prasinezumab in the U.S.

Negatives

• The Phase IIb PADOVA study's primary endpoint (time to confirmed motor progression) missed statistical significance (p=0.0657) in the overall population.

Risks

• Forward-looking statements are based on estimates, projections, and assumptions that may prove not to be accurate, and actual results could differ materially.
• Known and unknown risks, uncertainties, and other factors, including those described in the Risk Factors sections of Prothena's SEC filings, could impact future outcomes.

Future Outlook

Roche plans to advance prasinezumab into Phase III development for early-stage Parkinson's disease, with ongoing open-label extension studies for long-term safety and efficacy. The goal is to potentially deliver the first disease-modifying treatment option for Parkinson's disease.

Management Comments

• "As pioneers in developing the first anti-alpha synuclein targeting antibody, we are excited to see Roche advancing prasinezumab into Phase III development, with the potential to deliver the first disease-modifying treatment option to the millions of individuals living with Parkinsons disease and their families," stated Gene Kinney, Ph.D., President and Chief Executive Officer, Prothena.

Industry Context

Parkinson's disease is a chronic, progressive, and debilitating neurodegenerative disease affecting over 10 million people worldwide, with increasing prevalence. While symptomatic treatments exist, there are currently no therapies that slow down or stop the clinical progression of the disease, highlighting a significant unmet medical need that prasinezumab aims to address by targeting a known biological driver.

Comparison to Industry Standards

• The document does not provide specific comparable companies, projects, or results for direct comparison to industry standards. It focuses on the internal clinical trial data and the drug's potential within the Parkinson's disease therapeutic landscape.

Stakeholder Impact

• Shareholders: Positive impact due to the advancement of a key pipeline asset to Phase III, increasing the potential for significant future milestone payments and royalties.
• Patients with Parkinson's disease: Potential for a new, disease-modifying treatment option, addressing a significant unmet medical need.
• Employees: Continued work on a promising therapeutic program, potentially leading to long-term growth and stability.

Next Steps

• Roche will advance prasinezumab into Phase III development for early-stage Parkinson's disease.
• Ongoing open-label extension (OLE) studies for PASADENA and PADOVA will continue to evaluate the long-term safety and efficacy of prasinezumab.

Key Dates

Recommendation

Keywords

Prothena, Roche, prasinezumab, Parkinson's disease, Phase III, clinical trial, alpha-synuclein, neurodegenerative, biotechnology, PADOVA study, PASADENA study, monoclonal antibody